Why the study?
What are the haemodynamic effects of intravenous encainide, flecainide, lorcainide, and tocainide in humans?
What are the haemodynamic effects of intravenous encainide, flecainide, lorcainide, and tocainide in humans?
Intravenous encainide, flecainide, lorcainide, and tocainide exert moderate negative inotropic effects, but are generally well tolerated haemodynamically in patients without severe cardiac dysfunction.
Answers are grounded in this paper and cite their sources.
May warrant caution in reduced LVEF despite moderate effects; leaves open prospective validation in contemporary arrhythmia care.
The haemodynamic effects of encainide, flecainide, lorcainide and tocainide in man are reviewed. Most of the investigations discussed are acute intervention studies after intravenous administration of the drugs. With all four drugs, haemodynamic changes, when present, were moderate. In most studies a decrease in left ventricular maximal dp/dt is demonstrated, suggesting a negative inotropic action. Left ventricular filling pressures are unchanged or slightly increased. A small decrease in cardiac performance, as determined by measurements of cardiac output and left ventricular ejection fraction, is usually observed, while systemic vascular resistance is increased or remains unchanged. Haemodynamic deterioration and/or hypotensive reactions after intravenous administration of any of the above drugs are uncommon in patients without severe cardiac dysfunction. Conclusions relative to drug safety in frank congestive failure are not warranted, in view of the small number of patients studied. While comparative studies between the drugs discussed have not been performed, the data presented here indicate that, on the basis of haemodynamic action, no one drug can be preferred above the other.
No takes yet. Share an insight, caveat, or question.
Vanhaleweyk et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: